ArticlePloS one2011
Micro-CT based experimental liver imaging using a nanoparticulate contrast agent: a longitudinal study in mice.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 94 citations in OpenAlex.
- In vivo imaging of central nervous system fluid spaces using synchrotron radiation-based micro computed tomography.Nature communications · 2026Article
- Article
- Contrast-enhanced photon-counting micro-CT of tumor xenograft models.Physics in medicine and biology · 2024Article
- Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives.Journal of nanobiotechnology · 2024Review
- Comparison of micro-CT image enhancement after use of different vascular casting agents.Quantitative imaging in medicine and surgery · 2024Article
- Article
- Contrast-enhanced photon-counting micro-CT of tumor xenograft models.bioRxiv : the preprint server for biology · 2024Article
- Usefulness of microfocus computed tomography in life science research: preliminary study using murine micro-hepatic tumor models.Surgery today · 2022Article
- Intrinsic Respiratory Gating for Simultaneous Multi-Mouse μCT Imaging to Assess Liver Tumors.Frontiers in medicine · 2022Article
- CT vs. bioluminescence: A comparison of imaging techniques for orthotopic prostate tumors in mice.PloS one · 2022Article
- Carbon Quantum Dots Conjugated Rhodium Nanoparticles as Hybrid Multimodal Contrast Agents.Nanomaterials (Basel, Switzerland) · 2021Article
- Nanoparticles as a Tool in Neuro-Oncology Theranostics.Pharmaceutics · 2021Review
- Article
- Computed tomography imaging of macrophage phagocytic activity in abdominal aortic aneurysm.Theranostics · 2021Article
- Anti-Tumoral and Anti-Angiogenic Effects of Low-DilutedFrontiers in oncology · 2021Article
- Initial joint bleed volume in a delayed on-demand treatment setup correlates with subsequent synovial changes in hemophilic mice.Animal models and experimental medicine · 2020Article
- Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma.Journal of translational medicine · 2020Article
- Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography.iScience · 2019Article
- Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice.Journal of visualized experiments : JoVE · 2019Article
- In Vivo Tracking of Tissue Engineered Constructs.Micromachines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicro-CT imaging of liver disease in mice relies on high soft tissue contrast to detect small lesions like liver metastases. Purpose of this study was to characterize the localization and time course of contrast enhancement of a nanoparticular alkaline earth metal-based contrast agent (VISCOVER ExiTron nano) developed for small animal liver CT imaging. METHODOLOGY: ExiTron nano 6000 and ExiTron nano 12000, formulated for liver/spleen imaging and angiography, respectively, were intravenously injected in C57BL/6J-mice. The distribution and time course of contrast enhancement were analysed by repeated micro-CT up to 6 months. Finally, mice developing liver metastases after intrasplenic injection of colon carcinoma cells underwent longitudinal micro-CT imaging after a single injection of ExiTron nano. PRINCIPAL
findingsAfter a single injection of ExiTron nano the contrast of liver and spleen peaked after 4-8 hours, lasted up to several months and was tolerated well by all mice. In addition, strong contrast enhancement of abdominal and mediastinal lymph nodes and the adrenal glands was observed. Within the first two hours after injection, particularly ExiTron nano 12000 provided pronounced contrast for imaging of vascular structures. ExiTron nano facilitated detection of liver metastases and provided sufficient contrast for longitudinal observation of tumor development over weeks.
conclusionsThe nanoparticulate contrast agents ExiTron nano 6000 and 12000 provide strong contrast of the liver, spleen, lymph nodes and adrenal glands up to weeks, hereby allowing longitudinal monitoring of pathological processes of these organs in small animals, with ExiTron nano 12000 being particularly optimized for angiography due to its very high initial vessel contrast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.